Vaccines against chlamydial infection

A Chlamydia trachomatis, immunogenicity technology, applied in the direction of Chlamydia antigen components, vaccines, antibody medical components, etc., can solve the problems such as no special public treatment of eye infections

Inactive Publication Date: 2009-09-02
GLAXOSMITHKLINE BIOLOGICALS SA +1
View PDF69 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] International Patent Application No. PCT / US2006 / 010793, Publication No. WO2006 / 104890, discloses combinations of Chlamydia antigens for the prevention and / or treatment of Chlamydia infections, but does not specifically disclose their use for the treatment of ocular infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccines against chlamydial infection
  • Vaccines against chlamydial infection
  • Vaccines against chlamydial infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0395] Example 1: Sequence comparison of Ct-089, Ct-858 and Ct-875

[0396] Chlamydia trachomatis serotype E is a common ocular serotype and was chosen as the basis for other sequence comparisons.

[0397] Multiple alignments of amino acid sequences for comparison have been performed using the CLUSTAL W program available from the Lasergene software package, version 5.0 (marketed by DNASTAR, Inc., Madison, WI). The basic multiple alignment algorithm involves a three-step process: all sequence pairs are aligned separately to compute a distance matrix that yields the divergence of each pair of sequences, then a guide tree is computed from the distance matrix and finally the sequences are progressively aligned according to the guide tree. The CLUSTAL W algorithm is described in Thompson et al., Nuc. Acids Res. 22:4673-4680 (1994). The alignment is shown in Figure 1, 2a / 2b and 3a / 3b.

[0398] T-helper epitopes are peptides that bind HLA class II molecules and are recognized by T-...

Embodiment 2

[0399] Example 2: Eliciting a protective immune response against Chlamydia trachomatis infection in mice

[0400] Experiment overview

[0401] Female C57BL / 6 and C3H mice were inoculated with a combination of Ct-089, Ct-858 and Ct-875 proteins from serotype E formulated in adjuvant (two or three intramuscular immunizations, using two different dose level). Positive controls were vaccinated with UV-attenuated protomers from serotype A or K in adjuvant. A negative control group was vaccinated with adjuvant only.

[0402] Mice were infected by individual eye challenges with ocular serotypes A, B or ocular vaginal serotype K. The course of infection was monitored by using eye swabs.

[0403] method

[0404] test individual

[0405] 240, 6-week-old female mice (consisting of 144 C3H mice and 96 C57BL / 6 mice) were obtained from Charles River Laboratories (Wilmington, Massachusetts). Animals were divided into 30 groups of 8 mice each (18 groups of C3H mice and 12 groups of C57...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a method for the treatment or prevention of ocular Chlamydia trachomatis infection by the administration of a safe and effective amount of an immunogenic composition comprising one or more Chlamydia trachomatis proteins, immunogenic fragments thereof or polynucleotides encoding said proteins or fragments, selected from the list consisting of Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd).

Description

field of invention [0001] The present invention generally relates to the treatment or prevention of Chlamydia infection. In particular, the present invention relates to methods and related aspects of treating or preventing Chlamydia trachomatis infection. Background of the invention [0002] Chlamydia are intracellular bacterial pathogens that are the cause of a variety of important human and animal infections. [0003] Chlamydia trachomatis is spread from person to person through social or sexual contact. A large number of C. trachomatis serotypes exist, and although identification and classification of serotypes are still developing, at least 18 have been reported so far. Serotypes A to C are mainly associated with ophthalmic trachoma, serotypes D to K with ophthalmic diseases and serotypes L1 to L3 with lymphogranuloma venereum (LGV) (Brunham, RC et al. J. Nat. Rev. Immunol. 2005 5:149-161). However, the disease association is not absolute, for example, serotype B has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/118A61P31/04
CPCA61K2039/55572A61K2039/55555A61K2039/55577A61K2039/54A61K2039/53A61K39/118A61K2039/55566A61P27/00A61P27/02A61P31/04A61K48/00
Inventor M·阿尔德森R·科勒Y·洛贝J·-F·L·迈松纳夫P·梅滕斯P·普罗布斯特S·里德
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products